{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:25Z","timestamp":1794013285355,"version":"4.8.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-025-00708-x","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T12:35:50Z","timestamp":1740486950000},"page":"139-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8586-9930","authenticated-orcid":false,"given":"Stefania Angela","family":"Di Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aquilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-2234","authenticated-orcid":false,"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"17","key":"708_CR1","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/heartjnl-2020-318760","volume":"107","author":"C Packard","year":"2021","unstructured":"Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart. 2021;107(17):1369\u201375. https:\/\/doi.org\/10.1136\/heartjnl-2020-318760.","journal-title":"Heart"},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, ESC Scientific Document Group, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pcad.2020.12.008","volume":"67","author":"B Cybulska","year":"2021","unstructured":"Cybulska B, K\u0142osiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M, International Lipid Expert Panel (ILEP). How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis. 2021;67:65\u201374. https:\/\/doi.org\/10.1016\/j.pcad.2020.12.008.","journal-title":"Prog Cardiovasc Dis"},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000165","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, et al. American Heart Association Council on Arteriosclerosis,Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404\u201342. https:\/\/doi.org\/10.1161\/ATV.0000000000000165.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"22","key":"708_CR5","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1093\/eurheartj\/ehaa1080","volume":"42","author":"AD Karagiannis","year":"2021","unstructured":"Karagiannis AD, Mehta A, Dhindsa DS, Virani SS, Orringer CE, Blumenthal RS, Stone NJ, Sperling LS. How low is safe? The frontier of very low (<\u200930\u00a0mg\/dL) LDL cholesterol. Eur Heart J. 2021;42(22):2154\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1080.","journal-title":"Eur Heart J"},{"key":"708_CR6","first-page":"282","volume":"33","author":"SMT Islam","year":"2022","unstructured":"Islam SMT, Osa-Andrews B, Jones PM, Muthukumar AR, Hashim I, Cao J. Methods of low-density lipoprotein-cholesterol measurement: analytical and clinical applications. EJIFCC. 2022;33:282\u201394.","journal-title":"EJIFCC"},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/jcp-2022-208480","volume":"76","author":"J Martins","year":"2023","unstructured":"Martins J, Steyn N, Rossouw HM, Pillay TS. Best practice for LDL-cholesterol: when and how to calculate. J Clin Pathol. 2023;76:145\u201352. https:\/\/doi.org\/10.1136\/jcp-2022-208480.","journal-title":"J Clin Pathol"},{"issue":"6","key":"708_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","volume":"56","author":"WG Miller","year":"2010","unstructured":"Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56(6):977\u201386. https:\/\/doi.org\/10.1373\/clinchem.2009.142810.","journal-title":"Clin Chem"},{"key":"708_CR9","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. https:\/\/doi.org\/10.1161\/CIR.0000000000000624","DOI":"10.1161\/CIR.0000000000000624"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1093\/eurheartj\/ehad547","volume":"44","author":"S Taageby Nielsen","year":"2023","unstructured":"Taageby Nielsen S, Mohr Lytsen R, Strandkjar N, Juul Rasmussen I, Sillesen AS, V\u00f8gg ROB, et al. Significance of lipids, lipoproteins, and apolipoproteins during the first 14\u201316 months of life. Eur Heart J. 2023;44:4408\u201318. https:\/\/doi.org\/10.1093\/eurheartj\/ehad547.","journal-title":"Eur Heart J"},{"issue":"4746","key":"708_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.3513311","volume":"232","author":"MS Brown","year":"1986","unstructured":"Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34\u201347.","journal-title":"Science"},{"issue":"3","key":"708_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1753944710368206","volume":"4","author":"W Hochholzer","year":"2010","unstructured":"Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185\u201391.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"25","key":"708_CR13","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/eurheartj\/ehad371","volume":"44","author":"SS Martin","year":"2023","unstructured":"Martin SS, Niles JK, Kaufman HW, Awan Z, Elgaddar O, Choi R, et al. Lipid distributions in the Global Diagnostics Network across five continents. Eur Heart J. 2023;44(25):2305\u201318.","journal-title":"Eur Heart J"},{"issue":"4","key":"708_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1515\/cclm-2019-1253","volume":"58","author":"MR Langlois","year":"2020","unstructured":"Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496\u2013517.","journal-title":"Clin Chem Lab Med"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7:265.","journal-title":"Signal Transduct Target Ther"},{"key":"708_CR16","doi-asserted-by":"publisher","first-page":"17549","DOI":"10.1074\/jbc.REV120.010723","volume":"295","author":"LJ Sharpe","year":"2020","unstructured":"Sharpe LJ, Coates HW, Brown AJ. Post-translational control of the long and winding road to cholesterol. J Biol Chem. 2020;295:17549\u201359.","journal-title":"J Biol Chem"},{"key":"708_CR17","doi-asserted-by":"crossref","unstructured":"Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Cholesterol metabolism, pancreatic \u03b2-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis 2019;1865(9):2149\u201356.","DOI":"10.1016\/j.bbadis.2019.04.012"},{"issue":"1","key":"708_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12944-022-01751-6","volume":"21","author":"G P\u00e4th","year":"2022","unstructured":"P\u00e4th G, Perakakis N, Mantzoros CS, Seufert J. PCSK9 inhibition and cholesterol homeostasis in insulin producing \u03b2-cells. Lipids Health Dis. 2022;21(1):138.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"708_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.chembiol.2010.10.009","volume":"17","author":"M Matsui","year":"2010","unstructured":"Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol. 2010;17(12):1344\u201355.","journal-title":"Chem Biol"},{"issue":"4","key":"708_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225\u201345.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"708_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-015-0463-z","volume":"110","author":"R Schulz","year":"2015","unstructured":"Schulz R, Schl\u00fcter K-D, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110:1\u201319.","journal-title":"Basic Res Cardiol"},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/joim.12614","volume":"281","author":"AG Olsson","year":"2017","unstructured":"Olsson AG, Angelin B, Assmann G, Binder CJ, Bj\u00f6rkhem I, Cedazo-Minguez A, et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med. 2017;281:534\u201353.","journal-title":"J Intern Med"},{"issue":"10","key":"708_CR23","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43(10):e404\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"708_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jacl.2022.08.009","volume":"16","author":"C Bredefeld","year":"2022","unstructured":"Bredefeld C, Hussain MM, Averna M, Black DD, Brin MF, Burnett JR, et al. Guidance for the diagnosis and treatment of hypolipidemia disorders. J Clin Lipidol. 2022;16(6):797\u2013812.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"708_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/17446651.2023.2204932","volume":"18","author":"PK Gill","year":"2023","unstructured":"Gill PK, Hegele RA. Low cholesterol states: clinical implications and management. Expert Rev Endocrinol Metab. 2023;18(3):241\u201353.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"708_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern African population. Atherosclerosis. 2007;193:445\u20138.","journal-title":"Atherosclerosis"},{"key":"708_CR27","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423\u20137.","journal-title":"BMJ"},{"issue":"25","key":"708_CR28","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"708_CR29","doi-asserted-by":"publisher","first-page":"e002162","DOI":"10.1161\/CIRCGEN.118.002162","volume":"11","author":"AS Rao","year":"2018","unstructured":"Rao AS, Lindholm D, Rivas MA, Knowles JW, Montgomery SB, Ingelsson E. Large-scale phenome-wide Association study of PCSK9 variants demonstrates Protection Against ischemic stroke. Circ Genom Precis Med. 2018;11(7):e002162.","journal-title":"Circ Genom Precis Med"},{"issue":"5","key":"708_CR30","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1212\/WNL.0000000000007853","volume":"93","author":"C Ma","year":"2019","unstructured":"Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019;93(5):e445\u201357.","journal-title":"Neurology"},{"issue":"12","key":"708_CR31","doi-asserted-by":"publisher","first-page":"e0279381","DOI":"10.1371\/journal.pone.0279381","volume":"17","author":"A Aman","year":"2022","unstructured":"Aman A, Slob EAW, Ward J, Cullen B, Graham N, Lyall DM, et al. Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based mendelian randomization. PLoS ONE. 2022;17(12):e0279381.","journal-title":"PLoS ONE"},{"issue":"13","key":"708_CR32","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and risk of type 2 diabetes: a Meta-analysis. JAMA. 2016;316(13):1383\u201391.","journal-title":"JAMA"},{"key":"708_CR33","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0002-9343(89)80596-0","volume":"87","author":"RJ Gerson","year":"1989","unstructured":"Gerson RJ, Macdonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl\u2010coenzyme a reductase inhibitors. Am J Med. 1989;87:S28\u201338.","journal-title":"Am J Med"},{"issue":"12","key":"708_CR34","doi-asserted-by":"publisher","first-page":"e025361","DOI":"10.1161\/JAHA.122.025361","volume":"11","author":"J Ghouse","year":"2022","unstructured":"Ghouse J, Ahlberg G, Skov AG, Bundgaard H, Olesen MS. Association of common and rare genetic variation in the 3-Hydroxy-3-Methylglutaryl coenzyme a reductase gene and cataract risk. J Am Heart Assoc. 2022;11(12):e025361.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"708_CR35","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholes- terolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"5","key":"708_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1210\/jcem-50-5-977","volume":"50","author":"DR Illingworth","year":"1980","unstructured":"Illingworth DR, Orwoll ES, Connor WE. Impaired cortisol secretion in abetalipoproteinemia. J Clin Endocrinol Metab. 1980;50(5):977\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1210\/jcem-54-1-27","volume":"54","author":"DR Illingworth","year":"1982","unstructured":"Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab. 1982;54:27\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"708_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/clc.23935","volume":"46","author":"NR Desai","year":"2023","unstructured":"Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023;46(1):13\u201321.","journal-title":"Clin Cardiol"},{"issue":"10","key":"708_CR39","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43(10):e404\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"708_CR40","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s12276-024-01273-4","volume":"56","author":"KC Shin","year":"2024","unstructured":"Shin KC, Ali Moussa HY, Park Y. Cholesterol imbalance and neurotransmission defects in neurodegeneration. Exp Mol Med. 2024;56(8):1685\u201390.","journal-title":"Exp Mol Med"},{"issue":"2","key":"708_CR41","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1124\/jpet.104.075028","volume":"312","author":"LN Johnson-Anuna","year":"2005","unstructured":"Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005;312(2):786\u201393.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"708_CR42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S2215-0366(20)30311-4","volume":"7","author":"Y Molero","year":"2020","unstructured":"Molero Y, Cipriani A, Larsson H, Lichtenstein P, D\u2019Onofrio BM, Fazel S. Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study. Lancet Psychiatry. 2020;7(11):982\u201390.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"708_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12944-022-01645-7","volume":"21","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Liu Z, Wang Q, Li X. Low cholesterol is not associated with depression: data from the 2005\u20132018 National Health and Nutrition Examination Survey. Lipids Health Dis. 2022;21(1):35.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"708_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41591-019-0366-x","volume":"25","author":"L Sun","year":"2019","unstructured":"Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. Nat Med. 2019;25(4):569\u201374.","journal-title":"Nat Med"},{"issue":"5","key":"708_CR45","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jacl.2018.06.011","volume":"12","author":"X Zhang","year":"2018","unstructured":"Zhang X, Liu J, Wang M, Qi Y, Sun J, Liu J, et al. Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China. J Clin Lipidol. 2018;12(5):1179\u2013e11894.","journal-title":"J Clin Lipidol"},{"issue":"10059","key":"708_CR46","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532\u201361.","journal-title":"Lancet"},{"issue":"4","key":"708_CR47","doi-asserted-by":"publisher","first-page":"e030714","DOI":"10.1161\/JAHA.123.030714","volume":"13","author":"S B\u00e9trisey","year":"2024","unstructured":"B\u00e9trisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, et al. Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and Meta-analysis of Randomized controlled trials. J Am Heart Assoc. 2024;13(4):e030714. https:\/\/doi.org\/10.1161\/JAHA.123.030714.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"708_CR48","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacl.2018.02.002","volume":"12","author":"JM Dobrzynski","year":"2018","unstructured":"Dobrzynski JM, Kostis JB, Sargsyan D, Zinonos S, Kostis WJ. Effect of cholesterol lowering with statins or proprotein convertase subtilisin\/kexin type 9 antibodies on cataracts: a meta-analysis. J Clin Lipidol. 2018;12(3):728\u201333.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"708_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12886-023-03012-1","volume":"23","author":"G Suc","year":"2023","unstructured":"Suc G, Schwartz GG, Goodman SG, Jukema JW, Manvelian G, Poulouin Y, et al. ODYSSEY OUTCOMES investigators. Effect of alirocumab on cataracts in patients with acute coronary syndromes. BMC Ophthalmol. 2023;23(1):279.","journal-title":"BMC Ophthalmol"},{"key":"708_CR50","doi-asserted-by":"publisher","first-page":"e021496","DOI":"10.1136\/bmjopen-2018-021496","volume":"8","author":"S Li","year":"2018","unstructured":"Li S, Li D, Zhang Y, Teng J, Shao M, Cao W. Association between serum lipids concentration and patients with age-related cataract in China: a cross-sectional, case-control study. BMJ Open. 2018;8:e021496.","journal-title":"BMJ Open"},{"key":"708_CR51","doi-asserted-by":"crossref","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81.","DOI":"10.1161\/ATV.0000000000000073"},{"issue":"5","key":"708_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","volume":"69","author":"JG Robinson","year":"2017","unstructured":"Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, et al. Safety of very low low-density lipoprotein cholesterol levels with Alirocumab: Pooled Data from Randomized trials. J Am Coll Cardiol. 2017;69(5):471\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"708_CR53","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"708_CR54","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, Nissen SE. CLEAR OUTCOMES committees and investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12(1):19\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"708_CR55","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","volume":"82","author":"RS Wright","year":"2023","unstructured":"Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023;82(24):2251\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"708_CR56","doi-asserted-by":"publisher","first-page":"20964","DOI":"10.1002\/cam4.6649","volume":"12","author":"L Li","year":"2023","unstructured":"Li L, Yu Z, Ren J, Niu T. Low cholesterol levels are associated with increasing risk of plasma cell neoplasm: a UK biobank cohort study. Cancer Med. 2023;12(22):20964\u201375.","journal-title":"Cancer Med"},{"key":"708_CR57","doi-asserted-by":"publisher","first-page":"e57191","DOI":"10.7554\/eLife.57191","volume":"9","author":"P Carter","year":"2020","unstructured":"Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the effect of statins on cancer risk using genetic variants from a mendelian randomization study in the UK Biobank. Elife. 2020;9:e57191.","journal-title":"Elife"},{"issue":"15","key":"708_CR58","doi-asserted-by":"publisher","first-page":"e023690","DOI":"10.1161\/JAHA.121.023690","volume":"11","author":"S Rong","year":"2022","unstructured":"Rong S, Li B, Chen L, Sun Y, Du Y, Liu B, et al. Association of low-density lipoprotein cholesterol levels with more than 20-Year risk of cardiovascular and all-cause mortality in the general population. J Am Heart Assoc. 2022;11(15):e023690.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"708_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41598-023-50931-6","volume":"14","author":"S Kim","year":"2024","unstructured":"Kim S, Kim G, Cho SH, Oh R, Kim JY, Lee YB, et al. Association between total cholesterol levels and all-cause mortality among newly diagnosed patients with cancer. Sci Rep. 2024;14(1):58.","journal-title":"Sci Rep"},{"issue":"18","key":"708_CR60","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, et al. PACMAN-AMI collaborators. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"issue":"7","key":"708_CR61","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of Evolocumab on Coronary Plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"15","key":"708_CR62","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo P, Basile C, Galasso G, Bellino M, D\u2019Elia D, Patti G, et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31(15):1806\u201316. https:\/\/doi.org\/10.1093\/eurjpc\/zwae170.","journal-title":"Eur J Prev Cardiol"},{"issue":"15","key":"708_CR63","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/eurjpc\/zwae206","volume":"31","author":"A Pirillo","year":"2024","unstructured":"Pirillo A, Catapano AL. Proprotein convertase subtilisisn\/kexin type 9 inhibitors: the earlier the better? Eur J Prev Cardiol. 2024;31(15):1817\u20139. https:\/\/doi.org\/10.1093\/eurjpc\/zwae206.","journal-title":"Eur J Prev Cardiol"},{"issue":"10106","key":"708_CR64","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, FOURIER Investigators, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)32290-0.","journal-title":"Lancet"},{"issue":"9","key":"708_CR65","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1714\/4318.43039","volume":"25","author":"SA Di Fusco","year":"2024","unstructured":"Di Fusco SA, Leggio M, Gil Ad V, Giubilato S, Aquilani S, Nardi F, et al. Livelli Di colesterolo bassi e molto bassi: cosa \u00e8 necessario sapere. G Ital Cardiol (Rome). 2024;25(9):650\u20139. https:\/\/doi.org\/10.1714\/4318.43039.","journal-title":"G Ital Cardiol (Rome)"},{"issue":"8","key":"708_CR66","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2459\/JCM.0000000000001175","volume":"22","author":"F Colivicchi","year":"2021","unstructured":"Colivicchi F, Di Fusco SA, Arca M, Leggio M, Caldarola P, Murrone A, et al. Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol in clinical practice: ANMCO position paper. J Cardiovasc Med. 2021;22(8):609\u201317. https:\/\/doi.org\/10.2459\/JCM.0000000000001175.","journal-title":"J Cardiovasc Med"},{"issue":"10384","key":"708_CR67","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE, PROMINENT REDUCE-IT, Investigators STRENGTH. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401(10384):1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(23)00215-5.","journal-title":"Lancet"},{"issue":"1","key":"708_CR68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/heartjnl-2021-320708","volume":"109","author":"SA Di Fusco","year":"2022","unstructured":"Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, et al. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18\u201325.","journal-title":"Heart"},{"key":"708_CR69","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/j.ajpc.2022.100456","volume":"13","author":"MJ Blaha","year":"2022","unstructured":"Blaha MJ, Abdelhamid M, Santilli F, Shi Z, Sibbing D. Advanced subclinical atherosclerosis: a novel category within the cardiovascular risk continuum with distinct treatment implications. Am J Prev Cardiol. 2022;13:100456.","journal-title":"Am J Prev Cardiol"},{"issue":"24","key":"708_CR70","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.jacc.2017.10.024","volume":"70","author":"L Fern\u00e1ndez-Friera","year":"2017","unstructured":"Fern\u00e1ndez-Friera L, Fuster V, L\u00f3pez-Melgar B, Oliva B, Garc\u00eda-Ruiz JM, Mendiguren J, et al. Normal LDL-Cholesterol levels are Associated with subclinical atherosclerosis in the absence of risk factors. J Am Coll Cardiol. 2017;70(24):2979\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"708_CR71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1471-2261-14-60","volume":"14","author":"WQ Gao","year":"2014","unstructured":"Gao WQ, Feng QZ, Li YF, Li YX, Huang Y, Chen YM, et al. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc Disord. 2014;14:60. https:\/\/doi.org\/10.1186\/1471-2261-14-60.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"708_CR72","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/ATVBAHA.123.320065","volume":"44","author":"KJ Williams","year":"2024","unstructured":"Williams KJ. Eradicating atherosclerotic events by targeting early subclinical disease: it is time to retire the therapeutic paradigm of too much, too late. Arterioscler Thromb Vasc Biol. 2024;44(1):48\u201364. https:\/\/doi.org\/10.1161\/ATVBAHA.123.320065.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"708_CR73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2018.04.021","volume":"274","author":"M Al Rifai","year":"2018","unstructured":"Al Rifai M, Martin SS, McEvoy JW, Nasir K, Blankstein R, Yeboah J, et al. The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol\u2009<\u200970\u00a0mg\/dL: the multi-ethnic study of atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Atherosclerosis. 2018;274:61\u20136.","journal-title":"Atherosclerosis"},{"issue":"1","key":"708_CR74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4236\/wjcd.2022.121002","volume":"12","author":"J Giannini","year":"2022","unstructured":"Giannini J, Padilla J, Eaton RP, Gonzales K, Schade DS. Prevention of coronary heart disease: a translational clinical challenge. World J Car Diovasc Dis. 2022;12(1):11\u201323.","journal-title":"World J Car Diovasc Dis"},{"issue":"1","key":"708_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","volume":"15","author":"CE Orringer","year":"2021","unstructured":"Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33\u201360.","journal-title":"J Clin Lipidol"},{"key":"708_CR76","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2022.02.006","volume":"347","author":"O Dzaye","year":"2022","unstructured":"Dzaye O, Razavi AC, Michos ED, Mortensen MB, Dardari ZA, Nasir K, et al. Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial. Atherosclerosis. 2022;347:70\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.02.006.","journal-title":"Atherosclerosis"}],"container-title":["High Blood Pressure &amp; Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00708-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-025-00708-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-025-00708-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T06:17:22Z","timestamp":1741501042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-025-00708-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":76,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s40292-025-00708-x","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. Outside of the purpose of this manuscript, MV reports honoraria for speaking bureau or advisory board by Astra Zeneca, Bayer, Menarini Int, Sanofi, Servier, Glaxo, Pfizer, Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}